You are here: Industry Insights > SAA

News List

Novartis receives European Commission approval for self-administration of Xolair® across all indications en-cphi.cn
December 14, 2018
Novartis today announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their o
Novartis Receives EC Approval for Self-Administration of Xolair across all Indications americanpharmaceuticalreview
December 14, 2018
Novartis announced that the European Commission (EC) has approved Xolair (omalizumab) prefilled syringe (PFS) for self-administration.....
EC approves self-administration of Novartis’ Xolair pharmaceutical-technology
December 14, 2018
The European Commission (EC) has approved the prefilled syringe (PFS) of Novartis’ Xolair (omalizumab) medication for self-administration by patients with ......
Novartis' Promacta cleared by FDA for first-line use in severe aplastic anaemia pharmafile
November 20, 2018
Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with standard immunosuppressive therapy (IST) for the first-line treatment of severe aplastic anaemia (SAA).
Novartis’ eltrombopag in SAA pharmatimes
April 21, 2017
Novartis has announced the publication of data showing high response rates in patients with the rare...